Objectives To perform a systematic review and network meta‐analysis to compare the
efficacy and safety of currently available treatments for the management of metastatic …

Importance Immune checkpoint inhibitors have been approved for use as a second-line
therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib …

Background In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival
benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted …

To gain insights on the diverse practice patterns and treatment pathways for prostate cancer
(PC) in India, the Urological Cancer Foundation convened the first Indian survey to discuss …

Objective We evaluate cost‐effectiveness of primary treatments for localised prostate cancer
by uniquely combining prospectively collected real‐world outcomes and costs from UCSF …

Background The optimal therapeutic strategies for patients with metastatic hormone-
sensitive prostate cancer (mHSPC) followed by metastatic castrate-resistant prostate cancer …

Background Prostate-specific antigen (PSA) and prostate health index (PHI) have been
used as biomarkers for prostate cancer detection. In this study, we aimed to evaluate the …

Objectives We aimed to compare the economic value of chemotherapy plus anti-epidermal
growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with …

Methods We used a state-transition model with probabilistic analysis to compare
apalutamide plus ADT, as compared to ADT alone, for mCSPC patients over a time horizon …

Abiraterone acetate in combination with prednisone is approved for locally advanced as well
as metastatic (hormone-sensitive and castrate-resistant) prostate cancer, with overall or …